EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of ISZ-sTRAIL Protein as a Potent Anticancer Agent for EML4-ALK-Positive Non-Small-Cell Lung Cancer

Junfeng Hu, Junhui Guo, Tian Qin, Xiuping Mao, Zi Liu iD, Liang Ma iD

Molecules · 2026

DOI: 10.3390/molecules31111870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Junfeng Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'ansha…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Oncogene Proteins, Fusion, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EML4-ALK-positive lung cancer represents an important molecular subtype of non-small-cell lung cancer (NSCLC) that initially responds to ALK inhibitors but invariably develops resistance, highlighting the need for novel targeted therapeutic strategies. Death receptors DR4 and DR5 are frequently upregulated in malignancies and can selectively induce tumor cell apoptosis upon binding TRAIL. ISZ-sTRAIL, a trimer-stabilized soluble TRAIL fusion protein, exhibits potent antitumor effects via DR4/DR5 signaling activation. However, the expression status of DR4/DR5 in EML4-ALK-positive NSCLC cells and the therapeutic potential of targeting this pathway remain poorly defined. In this study, we evaluated DR4/DR5 protein expression in EML4-ALK-positive NSCLC cells and investigated the antitumor effect of ISZ-sTRAIL produced in an Escherichia coli expression system. Our results showed that DR4 and DR5 were abundantly expressed in EML4-ALK-positive NCI-H2228 and NCI-H3122 cells compared with normal human bronchial epithelial 16HBE cells. Furthermore, ISZ-sTRAIL significantly suppressed the proliferation of NCI-H2228 and NCI-H3122 cells, with IC50 values of 4.51 ± 0.22 nM and 14.98 ± 3.34 nM, respectively, while showing low cytotoxicity toward normal 16HBE cells (IC50 > 1 μM). Moreover, ISZ-sTRAIL induced caspase-dependent apoptosis in both cell lines via activation of extrinsic and intrinsic pathway, and these effects were markedly abrogated by the pan-caspase inhibitor Z-VAD. These findings identify DR4/DR5 as a potential therapeutic target and provide preclinical evidence for the development of TRAIL-based strategies in the treatment of EML4-ALK-positive NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungOncogene Proteins, FusionLung NeoplasmsAntineoplastic AgentsRecombinant Fusion ProteinsTNF-Related Apoptosis-Inducing LigandHumansCell Line, TumorApoptosisReceptors, TNF-Related Apoptosis-Inducing LigandCell ProliferationSignal Transduction

Stichwörter der Autor:innen

EML4-ALK-positive non-small-cell lung cancerISZ-sTRAIL proteinapoptosiscaspase activation

Substanzen

Oncogene Proteins, FusionEML4-ALK fusion protein, humanAntineoplastic AgentsRecombinant Fusion ProteinsReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing Ligand

Autor:innen und Institutionen

  • Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, China.

ORCID-Profile: Zi Liu, Liang Ma

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, J., Guo, J., Qin, T., Mao, X., Liu, Z., & Ma, L. (2026). Identification of ISZ-sTRAIL Protein as a Potent Anticancer Agent for EML4-ALK-Positive Non-Small-Cell Lung Cancer. Molecules. https://doi.org/10.3390/molecules31111870

Vancouver

Hu J, Guo J, Qin T, Mao X, Liu Z, Ma L. Identification of ISZ-sTRAIL Protein as a Potent Anticancer Agent for EML4-ALK-Positive Non-Small-Cell Lung Cancer. Molecules. 2026. doi:10.3390/molecules31111870

BibTeX
@article{Hu2026,
  author = {Hu, Junfeng and Guo, Junhui and Qin, Tian and Mao, Xiuping and Liu, Zi and Ma, Liang},
  title = {Identification of ISZ-sTRAIL Protein as a Potent Anticancer Agent for EML4-ALK-Positive Non-Small-Cell Lung Cancer},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31111870}
}
Kostenlos starten →